



# ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH  
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH  
INVEST & PARTNERING



## GRÜNBIOTICS

Medical Nutrition. Improving Lives.

## Grunbiotics

### Company Description

Grunbiotics is an Australian biotechnology company developing specialised medical nutrition products that, when added to existing patient therapy provide substantial improvements in the management and treatment of chronic health conditions.

The company's focus is on products that address nutritional deficiencies and metabolic imbalances prevalent in large healthcare markets with significant unmet needs.

Current target therapeutic areas include depression, Alzheimer's Dementia, and diabetic peripheral neuropathy.

Partnering with leading global pharmaceutical companies, Grunbiotics is at the forefront of the recognition that specialised nutrition provides a strong compliment to traditional drug therapies as part of a comprehensive treatment programme for optimal treatment outcomes.

The company's initial portfolio of products has been developed under an exclusive relationship with Merck. In Australia, Grunbiotics has partnered with Mylan, the world's 2<sup>nd</sup> largest generics and specialty pharmaceutical company and the largest provider of medicine to the Australian healthcare system, for distribution.

The products are based on strong clinical and scientific evidence, and are IP protected. Grunbiotics is based in Melbourne and proudly manufactures in Australia.

### Pipeline and Developments

**Neurofolin:** for dietary management of depression


Neurofolin addresses a complex folate deficiency found in many sufferers of depression, helping patients achieve and maintain remission. Neurofolin may be used alone or with other antidepressants. Neurofolin was released in Australia in September 2017, is currently undergoing regulatory approval for Europe and is due to be released in China in 2018.


**Neurothrive:** for dietary management of early memory loss and Alzheimer's Dementia.

Clinical trials with Neurothrive have demonstrated a halting of the the atrophication of the brain for approximately 50% of dementia sufferers. Neurothrive is due for release in Australia in 2018.

Other therapeutic areas of focus: Diabetes, peripheral neuropathy, oncology.

For more information, please visit [www.australiabiotechinvest.com.au](http://www.australiabiotechinvest.com.au)

 Follow us for the latest event update #AusBioInv



# ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong

15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH  
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH  
INVEST & PARTNERING



## What we are looking for:

A strategic investment partner to assist Grunbiotics to realise the large market opportunity that exists for the company's products in the Asia region.

Grunbiotics is seeking in the order of a \$1-2m total investment

## Contact:

Name: Jamie Hughes

Position: Managing Director

Company: Grunbiotics

Address: c/o CD&Co, Level 42, Rialto Tower South, 525 Collins St, Melbourne, Australia, VIC 3000

Website: [www.grunbiotics.com](http://www.grunbiotics.com)

Phone: +61 (03) 8692-0006

Email: [jhughes@grunbiotics.com](mailto:jhughes@grunbiotics.com)

For more information, please visit [www.australiabiotechinvest.com.au](http://www.australiabiotechinvest.com.au)



Follow us for the latest event update #AusBioInv